British Journal of Anaesthesia

Dr. David Yamane was awarded the Star Research Award at the 2024 Critical Care Congress for the presentation of the HYPERACT Study - a randomized controlled trial demonstrating Vapotherm's High Velocity Therapy effectively treats moderate-severe acute exa

Retrieved on: 
Wednesday, March 6, 2024
VAPO, Hospital, Incidence, Doctor of Philosophy, Periodic breathing, Randomized controlled trial, Critical care, ED, Society, Chronic obstructive pulmonary disease, SCCM, Face, Disease, Patient, Congress, OTCQX, British Journal of Anaesthesia, Mortality, Critical Care Medicine (journal), COPD, Pressure, PCO2

The award is in recognition of the HYPERACT study – a new multi-center, randomized controlled trial which offers high velocity therapy as an additional, more comfortable, option for clinicians treating acute exacerbations of moderate-severe COPD.

Key Points: 
  • The award is in recognition of the HYPERACT study – a new multi-center, randomized controlled trial which offers high velocity therapy as an additional, more comfortable, option for clinicians treating acute exacerbations of moderate-severe COPD.
  • Acute exacerbations of COPD contribute to over 600K emergency room (ER) visits and 140K deaths annually in the US alone.
  • "This study concludes that high velocity therapy provides similar clinical results and statistically superior patient reported comfort compared to mask-based therapies."
  • (3)
    Dr. Yamane was presented with the award at the 2024 Critical Care Congress on January 23rd, 2024, in Phoenix, AZ.

Philips Visual Patient Avatar pioneers at-a-glance patient data for faster, better decision-making in the operating room

Retrieved on: 
Friday, October 13, 2023
PHG, Partnership, American Society of Anesthesiologists, DRS, Perception, NYSE, Operating, Certified Registered Nurse Anesthetist, Structural load, BMC Medical Informatics and Decision Making, Philips, PST, MD, British Journal of Anaesthesia, Society, Safety, Hospital, patients, health, territories, ORS, Vital signs, Teaching hospital, Decision, Aircraft, Life, OR, Patient, AEX, Atmosphere, Hospital, Medical imaging, Nursing, Medical device, Anesthesiology

Visual Patient Avatar is designed to improve situational awareness with ground-breaking elegance by visualizing vital information through animations, colors and shapes.

Key Points: 
  • Visual Patient Avatar is designed to improve situational awareness with ground-breaking elegance by visualizing vital information through animations, colors and shapes.
  • By glancing at a monitor with Visual Patient Avatar, anesthesiologists and nurse anesthetists can recall and process critical data more quickly, efficiently and confidently – ultimately helping to save lives.
  • Visual Patient Avatar was designed in partnership with two clinicians at the Visualization Technology Research Group at the Institute of Anesthesiology, University Hospital of Zürich.
  • The inspiration for Visual Patient Avatar came from a hobby of the two clinicians, flying airplanes.

Publication on NanoMosaic Technology in the, "British Journal of Anaesthesia"

Retrieved on: 
Tuesday, September 20, 2022
Tau, Workflow, Time, Immunoassay, L.L.C, Entrepreneurship, Biomarker, Hospital, Dementia, Delirium, Annals of Surgery, Massachusetts General Hospital, Patient, PET, Nanoneedle, CEO, Serum, Cardiopulmonary bypass, Alzheimer's disease, British Journal of Anaesthesia, Harvard Medical School, Research, Plasma, Medical imaging, Tessie

BOSTON, Sept. 20, 2022 /PRNewswire/ -- With NanoMosaic's nanoneedle technology, researchers from Massachusetts General Hospital and Harvard Medical School detected Tau and phosphor-Tau proteins in serum samples from patients under major cardiac surgery with cardiopulmonary bypass. Elevation of Tau and phosphor-Tau proteins were observed before and after the surgery, and Tau protein is identified as a potential serum biomarker of delirium after cardiac surgery. The study has been published in the British Journal of Anaesthesia.

Key Points: 
  • The study has been published in the British Journal of Anaesthesia.
  • "NanoMosaic has implemented the tools and infrastructure to transition from the research bench to the clinic," Boyce concluded.
  • The proprietary technology enables rapid, end user customization for assay development for proteomic and/or nucleic acid content.
  • The NanoMosaic platform allows researchers to push the frontiers in biomarker discovery and diagnostics.

GE Healthcare Receives FDA Approval of First-Ever Software to Help Automate Anesthesia Delivery and Reduce Greenhouse Gas Emissions During Surgery

Retrieved on: 
Monday, April 4, 2022
FDA, Other Health, Technology, Surgery, Women, Medical Devices, Seniors, Hospitals, Men, Clinical Trials, Biotechnology, Science, Software, Consumer, Research, Health, GE Healthcare, LinkedIn, British Journal of Anaesthesia, World Health Organization, Multimedia, Aisi Hai Tanhai, NYSE, Patient, Hospital, Environment, General manager, World, Insight, Thomas Edison, Australian Society of Anaesthetists, Software, Health, Technology, Cone Health Women's Hospital, Safety, Control, Twitter, Ecosystem, Solution, News, Department, Haynes, FDA, Instagram, PMA, Medical device, Pharmaceutical industry, Brigham, Facebook, Anesthesia

GE Healthcare announced today the FDA pre-market approval (PMA) for its End-tidal (Et) Control software for general anesthesia delivery on its Aisys CS2 Anesthesia Delivery System.

Key Points: 
  • GE Healthcare announced today the FDA pre-market approval (PMA) for its End-tidal (Et) Control software for general anesthesia delivery on its Aisys CS2 Anesthesia Delivery System.
  • GE Healthcare is the only manufacturer approved to offer general anesthesia delivery with end-tidal concentration control in the U.S.
  • The Et Control software improves anesthesia delivery accuracy and simplifies workflows while reducing drug waste, lowering the cost of care and greenhouse gas emissions.
  • With this FDA approval, GE Healthcare will launch the Aisys CS2 Anesthesia Delivery System with Et Control in the U.S in the coming months.